Home > DNA/RNA Synthesis & > Oxaliplatin

Oxaliplatin

奥沙利铂,L-OHP

Oxaliplatin通过与DNA交联而抑制DNA合成。

目录号
EY1535
EY1535
EY1535
纯度
99.54%
99.54%
99.54%
规格
5 mg
50 mg
100 mg
原价
350
450
700
售价
350
450
700
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin and shows antitumor activity in cell line.

  • 体外研究

  • 体内研究

    水溶液

  • 激酶实验

  • 细胞实验

    ~100 μM

  • 动物实验

    10 mg/kg 每周腹腔注射

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Raymond E et al, Ann Oncol, 1998, 9(10), 1053-1071.
    [2] MacDonald, J.S., 2002. Cancer Invest. 20: 287-289.
    [3] Mani, S., et al. 2002. Cancer Invest. 20: 246-263.
    [4] Culy, C.R., et al. 2000. Drugs. 60: 895-924.

    分子式
    C8H14N2O4Pt    		 分子量
    397.29    		 CAS号
    61825-94-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    		 Water
    8 mg/ml    		 Ethanol
    Insoluble

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01042691 Unresectable Colorectal Liver Metastases Drug: Oxaliplatin David Bartlett|The Pittsburgh Foundation|Sanofi|University of Pittsburgh Phase 1 2003-05-01 2015-12-23
    NCT01558453 Relapsed Solid Tumor|Refractory Solid Tumor Drug: Oxaliplatin Sidnei Epelman|Hospital Santa Marcelina Phase 2 2011-03-01 2013-03-25
    NCT02284529 Stage-鈪?Colorectal Cancer Drug: Orectalip Sinphar Pharmaceutical Co., Ltd|Taichung Veterans General Hospital Phase 4 2012-10-01 2014-11-03
    NCT01608646 Gastrointestinal Cancer Drug: S-1 plus oxaliplatin Xijing Hospital Phase 2 2012-03-01 2012-05-28
    NCT02569723 Colon Adenocarcinoma Drug: Carbon C 14 Oxaliplatin|Drug: Oxaliplatin University of California, Davis|National Cancer Institute (NCI) 2015-10-01 2016-12-20
    NCT00183898 Gastric Cancer|Esophageal Cancer Drug: oxaliplatin, capecitabine University of Southern California|Sanofi|Roche Global Development|Bristol-Myers Squibb Phase 2 2004-12-01 2015-10-24
    NCT02062749 Colorectal Cancer Drug: Oxaliplatin M.D. Anderson Cancer Center Phase 1 2014-05-01 2016-09-23
    NCT02077998 Stage IV Breast Cancer Radiation: carbon C 14 oxaliplatin|Drug: oxaliplatin|Other: laboratory biomarker analysis University of California, Davis|National Cancer Institute (NCI) Early Phase 1 2015-05-01 2016-01-04
    NCT01106066 Phase I: To Determine the Maximum Tolerated Dose (MTD)|Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin Drug: Oxaliplatin, S-1, radiotherapy Samsung Medical Center Phase 1|Phase 2 2009-03-01 2013-06-12
    NCT02486198 Neurotoxicity Drug: placebo|Drug: GM|Drug: oxaliplatin-based chemotherapy Tianjin Medical University Cancer Institute and Hospital Phase 3 2015-05-01 2015-06-30
    NCT00677443 Colorectal Cancer Drug: S-1 & Oxaliplatin|Drug: Capecitabine & Oxaliplatin Samsung Medical Center|National Cancer Center, Korea|Seoul National University Bundang Hospital|Seoul National University Hospital|Gachon University Gil Medical Center|Yonsei University|Asan Medical Center|Chonnam National University Hospital Phase 3 2008-06-01 2013-06-12
    NCT00585078 Pancreatic Cancer Drug: Capecitabine|Drug: Oxaliplatin Beth Israel Deaconess Medical Center|Sanofi|Dana-Farber Cancer Institute Phase 2 2004-04-01 2017-02-23
    NCT00674206 Breast Cancer Drug: Gemcitabine|Drug: Oxaliplatin Emory University|Sanofi Phase 2 2008-10-01 2013-11-18
    NCT00954005 Indolent Lymphoma Drug: Therapy with Rituximab, Gemcitabine and Oxaliplatin German Low Grade Lymphoma Study Group Phase 1|Phase 2 2003-01-01 2015-08-17
    NCT00525005 Stomach Neoplasms Drug: DOS (Docetaxel, Oxaliplatin and S-1) Hallym University Medical Center|Asan Medical Center|Sanofi Phase 2 2007-08-01 2012-09-20
    NCT02289378 Docetaxel, Oxaliplatin and Fluorouracil Drug: Docetaxel, Oxaliplatin and 5-Fu Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 2014-11-01 2014-11-13
    NCT00557557 Colorectal Liver Metastases Drug: Drug: 5-FU|Drug: Drug: Oxaliplatin David Bartlett|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of Pittsburgh Phase 1 2007-07-01 2015-12-23
    NCT02557503 Advanced Adult Primary Liver Cancer Drug: Oxaliplatin and fluorouracil Zhu Xu|Beijing Cancer Hospital Phase 4 2015-01-01 2015-09-22
    NCT01067053 Metastatic Colorectal Cancer Drug: bevacizumab, capecitabine, oxaliplatin Grupo Espanol Multidisciplinario del Cancer Digestivo Phase 2 2009-11-01 2014-01-08
    NCT01090505 Gastric Cancer Drug: Drug: S-1 and oxaliplatin Chinese PLA General Hospital Phase 2 2009-11-01 2010-03-19
    NCT01370876 Cancer of the Head and Neck|Neoplasms, Head and Neck Drug: Oxaliplatin Nang Kuang Pharmaceutical Co., Ltd. Phase 2 2010-09-01 2013-12-09
    NCT02347904 Esophageal Cancer Drug: S-1 and Oxaliplatin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Celgene Corporation Phase 1 2014-12-01 2016-07-26

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：